Top Markets
#1 Audiera Audiera +33.84%
#2 TROLL TROLL +33.46%
#3 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +32.45%
#4 Bitcoin Cash Bitcoin Cash +32.20%
#5 GALA GALA +32.15%
#6 Fabric Protocol Fabric Protocol +31.41%
#7 B3 (Base) B3 (Base) +30.61%
#8 Tutorial Tutorial +28.97%
#9 Kamino Kamino +28.72%
#10 Bless Bless +28.27%
Coin of the day
Audiera Audiera
Settings
Language
ENGLISH
Currency
USD
Theme
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
Rank in Stocks #24577
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Share Price
$1.48
Last synced: 2025-03-24
Market Cap
$59.05M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
GB
Trade Achilles Therapeutics plc (ACHL)

Category

Healthcare
Revenue for Achilles Therapeutics plc (ACHL)
Revenue in Aug 2026 TTM: 0
According to Achilles Therapeutics plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Achilles Therapeutics plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH